Blood Cancer Journal最新文献

{"title":"Improving outcomes with anti-BCMA bispecific antibodies with attention to infection.","authors":"Andrew J Yee","doi":"10.1038/s41408-024-01091-x","DOIUrl":"10.1038/s41408-024-01091-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","authors":"Mazyar Shadman, Kwang W. Ahn, Manmeet Kaur, Lazaros Lekakis, Amer Beitinjaneh, Madiha Iqbal, Nausheen Ahmed, Brian Hill, Nasheed M. Hossain, Peter Riedell, Ajay K. Gopal, Natalie Grover, Matthew Frigault, Jonathan Brammer, Nilanjan Ghosh, Reid Merryman, Aleksandr Lazaryan, Ron Ram, Mark Hertzberg, Bipin Savani, Farrukh Awan, Farhad Khimani, Sairah Ahmed, Vaishalee P. Kenkre, Matthew Ulrickson, Nirav Shah, Mohamed A. Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani","doi":"10.1038/s41408-024-01084-w","DOIUrl":"https://doi.org/10.1038/s41408-024-01084-w","url":null,"abstract":"<p>In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood &amp; Marrow Transplant Research registry. Median follow-up was 49.7 months for the auto-HCT and 24.7 months for the CAR-T cohort. Patients ages 18 and 75 with a diagnosis of DLBCL were included if they received auto-HCT (<i>n</i> = 281) or commercial CAR-T (<i>n</i> = 79) while in a CR. Patients undergoing auto-HCT with only one prior therapy line and CAR-T patients with a previous history of auto-HCT treatment were excluded. Endpoints included Progression-free survival (PFS), relapse rate, non-relapse mortality (NRM) and overall survival (OS). In univariate analysis, treatment with auto-HCT was associated with a higher rate of 2-year PFS (66.2% vs. 47.8%; <i>p</i> &lt; 0.001), a lower 2-year cumulative incidence of relapse (27.8% vs. 48% ; <i>p</i> &lt; 0.001), and a superior 2-year OS (78.9% vs. 65.6%; <i>p</i> = 0.037). In patients with early (within 12 months) treatment failure, auto-HCT was associated with a superior 2-year PFS (70.9% vs. 48.3% ; <i>p</i> &lt; 0.001), lower 2-year cumulative incidence of relapse (22.8% vs. 45.9% ; <i>p</i> &lt; 0.001) and trend for higher 2-year OS (82.4% vs. 66.1% ; <i>p</i> = 0.076). In the multivariable analysis, treatment with auto-HCT was associated with a superior PFS (hazard ratio 1.83; <i>p</i> = 0.0011) and lower incidence of relapse (hazard ratio 2.18; <i>p</i> &lt; 0.0001) compared to CAR-T. In patients with relapsed LBCL who achieve a CR, treatment with auto-HCT is associated with improved clinical outcomes compared to CAR-T. These data support the consideration of auto-HCT in select patients with LBCL achieving a CR in the relapsed setting.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation","authors":"Jiayu Huang, Bingyang Shi, Suhui Yu, Mengxing Xue, Ling Wang, Jieling Jiang, Jiong Hu, Jun Zhu, Suning Chen, Lijing Shen, Weijie Cao, Yang Cao, Xiaoxia Hu","doi":"10.1038/s41408-024-01092-w","DOIUrl":"https://doi.org/10.1038/s41408-024-01092-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years.","authors":"Philipp Berning, Mathilde Fekom, Maud Ngoya, Anthony H Goldstone, Peter Dreger, Silvia Montoto, Hervé Finel, Evgenii Shumilov, Patrice Chevallier, Didier Blaise, Tim Strüssmann, Ben Carpenter, Edouard Forcade, Cristina Castilla-Llorente, Marek Trneny, Hervé Ghesquieres, Saveria Capria, Catherine Thieblemont, Igor Wolfgang Blau, Ellen Meijer, Annoek E C Broers, Anne Huynh, Denis Caillot, Wolf Rösler, Stephanie Nguyen Quoc, Jörg Bittenbring, Arnon Nagler, Jacques-Emmanuel Galimard, Bertram Glass, Anna Sureda, Norbert Schmitz","doi":"10.1038/s41408-024-01085-9","DOIUrl":"10.1038/s41408-024-01085-9","url":null,"abstract":"<p><p>Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018. The recent decline in transplants corresponds to increased CAR-T treatments (1117 cases in 2021). Median age for auto-HSCT rose from 42 (1990-1994) to 58 years (2015-2021), with peripheral blood becoming the primary stem cell source post-1994. Allo-HSCT median age increased from 36 (1990-1994) to 54 (2015-2021) years, with mobilized blood as the primary source post-1998 and reduced intensity conditioning post-2000. Unrelated and mismatched allo-HSCT accounted for 50% and 19% of allo-HSCT in 2015-2021. Three-year overall survival (OS) after auto-HSCT improved from 56% (1990-1994) to 70% (2015-2021), p < 0.001, with a decrease in relapse incidence (RI) from 49% to 38%, while non-relapse mortality (NRM) remained unchanged (4%). After allo-HSCT, 3-year-OS increased from 33% (1990-1999) to 46% (2015-2021) (p < 0.001); 3-year RI remained at 39% and 1-year-NRM decreased to 19% (p < 0.001). Our data reflect advancements over 32 years and >40,000 transplants, providing insights for evaluating emerging DLBCL therapies.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11226679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141537485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data","authors":"Richard Norris, John Jones, Erika Mancini, Timothy Chevassut, Fabio A. Simoes, Chris Pepper, Andrea Pepper, Simon Mitchell","doi":"10.1038/s41408-024-01090-y","DOIUrl":"https://doi.org/10.1038/s41408-024-01090-y","url":null,"abstract":"<p>Genetic heterogeneity and co-occurring driver mutations impact clinical outcomes in blood cancers, but predicting the emergent effect of co-occurring mutations that impact multiple complex and interacting signalling networks is challenging. Here, we used mathematical models to predict the impact of co-occurring mutations on cellular signalling and cell fates in diffuse large B cell lymphoma and multiple myeloma. Simulations predicted adverse impact on clinical prognosis when combinations of mutations induced both anti-apoptotic (AA) and pro-proliferative (PP) signalling. We integrated patient-specific mutational profiles into personalised lymphoma models, and identified patients characterised by simultaneous upregulation of anti-apoptotic and pro-proliferative (AAPP) signalling in all genomic and cell-of-origin classifications (8-25% of patients). In a discovery cohort and two validation cohorts, patients with upregulation of neither, one (AA or PP), or both (AAPP) signalling states had good, intermediate and poor prognosis respectively. Combining AAPP signalling with genetic or clinical prognostic predictors reliably stratified patients into striking prognostic categories. AAPP patients in poor prognosis genetic clusters had 7.8 months median overall survival, while patients lacking both features had 90% overall survival at 120 months in a validation cohort. Personalised computational models enable identification of novel risk-stratified patient subgroups, providing a valuable tool for future risk-adapted clinical trials.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141521301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2^V617F-induced myeloproliferative neoplasms.","authors":"Mengshi Hu, Tao Yang, Linyu Yang, Lu Niu, Jinbing Zhu, Ailin Zhao, Mingsong Shi, Xue Yuan, Minghai Tang, Jianhong Yang, Heying Pei, Zhuang Yang, Qiang Chen, Haoyu Ye, Ting Niu, Lijuan Chen","doi":"10.1038/s41408-024-01058-y","DOIUrl":"10.1038/s41408-024-01058-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are thrombosis, progression, and survival in ET predictable?","authors":"Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Ahamed Lebbe, Imane Bouhali, Mohammed Khalid, Richard T. Silver, Joseph M. Scandura","doi":"10.1038/s41408-024-01079-7","DOIUrl":"https://doi.org/10.1038/s41408-024-01079-7","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141448282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia","authors":"Maria L. Salustiano-Bandeira, Amanda Moreira-Aguiar, Diego A. Pereira-Martins, Juan L. Coelho-Silva, Isabel Weinhäuser, Pedro L. França-Neto, Aleide S. Lima, Ana S. Lima, Anemari R. Baccarin, Fernanda B. Silva, Manuela A. de Melo, Fernanda S. Niemann, Luciana Nardinelli, César A. Ortiz Rojas, Bruno K. Duarte, Aderson S. Araujo, Elisa A. Azevedo, Clarice N. Morais, Lorena L. Figueiredo-Pontes, Jan J. Schuringa, Gerwin Huls, Israel Bendit, Eduardo M. Rego, Sara T. Olalla Saad, Fabiola Traina, Marcos A. Bezerra, Antonio R. Lucena-Araujo","doi":"10.1038/s41408-024-01086-8","DOIUrl":"https://doi.org/10.1038/s41408-024-01086-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and outcomes in primary nervous system histiocytic neoplasms","authors":"Nabeela Nathoo, Joon H. Uhm, Alyx B. Porter, Julie Hammack, Kurt A. Jaeckle, Maciej M. Mrugala, Brian A. Crum, Eoin P. Flanagan, Sean J. Pittock, Gaurav Goyal, Jason R. Young, Matthew J. Koster, Robert Vassallo, Jay H. Ryu, Caroline J. Davidge-Pitts, Corrie Bach, Aishwarya Ravindran, Julio C. Sartori Valinotti, N. Nora Bennani, Jithma P. Abeykoon, Mithun V. Shah, C. Christopher Hook, Karen L. Rech, Ronald S. Go, W. Oliver Tobin","doi":"10.1038/s41408-024-01083-x","DOIUrl":"https://doi.org/10.1038/s41408-024-01083-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141430542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL","authors":"Kerstin Wenzl, Matthew E. Stokes, Joseph P. Novak, Allison M. Bock, Sana Khan, Melissa A. Hopper, Jordan E. Krull, Abigail R. Dropik, Janek S. Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C. Chris Huang, Matthew J. Maurer, Lisa Rimsza, Brian K. Link, Susan L. Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Andrew L. Feldman, Rebecca L. King, Grzegorz Nowakowski, James R. Cerhan, Anita K. Gandhi, Anne J. Novak","doi":"10.1038/s41408-024-01080-0","DOIUrl":"https://doi.org/10.1038/s41408-024-01080-0","url":null,"abstract":"<p>Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq. A combination of weighted gene correlation network analysis and differential gene expression analysis was used to identify a signature associated with high risk of early clinical failure independent of IPI and COO. Further analysis revealed the signature was associated with metabolic reprogramming and identified cases with a depleted immune microenvironment. Finally, WES data was integrated into the signature and we found that inclusion of <i>ARID1A</i> mutations resulted in identification of 45% of cases with an early clinical failure which was validated in external DLBCL cohorts. This novel and integrative approach is the first to identify a signature at diagnosis, in a real-world cohort of DLBCL, that identifies patients at high risk for early clinical failure and may have significant implications for design of therapeutic options.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":null,"pages":null},"PeriodicalIF":12.8,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141430526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}